Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Masking Game: Design of Activatable Antibodies and Mimetics for Selective Therapeutics and Cell Control
Roberta Lucchi, Jordi Bentanachs, Benjamí Oller‐Salvia
ACS Central Science (2021) Vol. 7, Iss. 5, pp. 724-738
Open Access | Times Cited: 64

Showing 1-25 of 64 citing articles:

Exploring the next generation of antibody–drug conjugates
Kyoji Tsuchikama, Yasuaki Anami, Summer Y. Y. Ha, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 3, pp. 203-223
Open Access | Times Cited: 188
Designing antibodies as therapeutics
Paul J. Carter, Arvind Rajpal
Cell (2022) Vol. 185, Iss. 15, pp. 2789-2805
Open Access | Times Cited: 146
The present and future of bispecific antibodies for cancer therapy
Christian Klein, Ulrich Brinkmann, Janice M. Reichert, et al.
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 4, pp. 301-319
Closed Access | Times Cited: 135
Genetically Engineering Cell Membrane‐Coated BTO Nanoparticles for MMP2‐Activated Piezocatalysis‐Immunotherapy
Qingshuang Tang, Suhui Sun, Ping Wang, et al.
Advanced Materials (2023) Vol. 35, Iss. 18
Closed Access | Times Cited: 69
The Dawn of a New Era: Targeting the “Undruggables” with Antibody-Based Therapeutics
Linghui Qian, Xuefen Lin, Xue Gao, et al.
Chemical Reviews (2023) Vol. 123, Iss. 12, pp. 7782-7853
Closed Access | Times Cited: 66
Cancer therapy with antibodies
Suman Paul, Maximilian F. Konig, Drew M. Pardoll, et al.
Nature reviews. Cancer (2024) Vol. 24, Iss. 6, pp. 399-426
Closed Access | Times Cited: 59
The Evolving Landscape of Antibody–Drug Conjugates: In Depth Analysis of Recent Research Progress
Janet M. Sasso, Rumiana Tenchov, Robert E. Bird, et al.
Bioconjugate Chemistry (2023) Vol. 34, Iss. 11, pp. 1951-2000
Open Access | Times Cited: 55
Bispecific and multispecific antibodies in oncology: opportunities and challenges
Maria-Elisabeth Goebeler, Gernot Stuhler, Ralf C. Bargou
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 7, pp. 539-560
Closed Access | Times Cited: 37
A pivotal decade for bispecific antibodies?
Marlena Surowka, Christian Klein
mAbs (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 20
Prodrug-based bispecific antibodies for cancer therapy: advances and future directions
Zhengdong Ai, Bing Wang, Yunlong Song, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access | Times Cited: 2
The present and future of immunocytokines for cancer treatment
Dennis Y. Gout, Lotte S. Groen, Marjolein van Egmond
Cellular and Molecular Life Sciences (2022) Vol. 79, Iss. 10
Open Access | Times Cited: 41
Antibody variable region engineering for improving cancer immunotherapy
Hantao Lou, Xuetao Cao
Cancer Communications (2022) Vol. 42, Iss. 9, pp. 804-827
Open Access | Times Cited: 40
Engineering cytokines for cancer immunotherapy: a systematic review
Yong Fu, Renhong Tang, Xiaofeng Zhao
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 28
Bispecific antibodies: advancing precision oncology
M. Zurita Herrera, G. Pretelli, Jayesh Desai, et al.
Trends in cancer (2024) Vol. 10, Iss. 10, pp. 893-919
Open Access | Times Cited: 15
Optogenetics with Atomic Precision─A Comprehensive Review of Optical Control of Protein Function through Genetic Code Expansion
Maura E. Charette, Carolyn Rosenblum, Olivia Shade, et al.
Chemical Reviews (2025)
Open Access | Times Cited: 1
Chemical generation of checkpoint inhibitory T cell engagers for the treatment of cancer
Péter A. Szijj, Melissa A. Gray, Mikaela K. Ribi, et al.
Nature Chemistry (2023) Vol. 15, Iss. 11, pp. 1636-1647
Open Access | Times Cited: 21
Modular Chemical Construction of IgG-like Mono- and Bispecific Synthetic Antibodies (SynAbs)
Fabien Thoreau, Péter A. Szijj, Michelle K. Greene, et al.
ACS Central Science (2023) Vol. 9, Iss. 3, pp. 476-487
Open Access | Times Cited: 20
Engineered antibody fusion proteins for targeted disease therapy
Aliyah B. Silver, Elissa K. Leonard, Joseph R. Gould, et al.
Trends in Pharmacological Sciences (2021) Vol. 42, Iss. 12, pp. 1064-1081
Open Access | Times Cited: 38
Constructing Photoactivatable Protein with Genetically Encoded Photocaged Glutamic Acid
Xiaochen Yang, Lei Zhao, Ying Wang, et al.
Angewandte Chemie International Edition (2023) Vol. 62, Iss. 40
Open Access | Times Cited: 13
Protein Modification at Tyrosine with Iminoxyl Radicals
Katsuya Maruyama, Takashi Ishiyama, Yohei Seki, et al.
Journal of the American Chemical Society (2021) Vol. 143, Iss. 47, pp. 19844-19855
Open Access | Times Cited: 31
Strategies to mitigate the on- and off-target toxicities of recombinant immunotoxins: an antibody engineering perspective
Mengyu Li, Sen Mei, Yi Yang, et al.
Antibody Therapeutics (2022) Vol. 5, Iss. 3, pp. 164-176
Open Access | Times Cited: 19
Chemoselective Caging of Carboxyl Groups for On‐Demand Protein Activation with Small Molecules
Yana Petri, Clair S. Gutierrez, Ronald T. Raines
Angewandte Chemie International Edition (2023) Vol. 62, Iss. 22
Open Access | Times Cited: 11
Site-Specific Antibody Prodrugs via S-Arylation: a Bioconjugation Approach Toward Masked Tyrosine Analogues
Jason Tao, Heemal H. Dhanjee, Michael W. Gribble, et al.
Journal of the American Chemical Society (2024) Vol. 146, Iss. 29, pp. 20080-20085
Closed Access | Times Cited: 4
Affibody-based HER2 prodrug shows conditional cytotoxic effect on HER2-positive cancer cells
Cornelia Westerberg, Anna Mestre Borras, Stefan Ståhl, et al.
Biochemical and Biophysical Research Communications (2025), pp. 151660-151660
Open Access
Multi-targeted, NOT gated CAR-T cells as a strategy to protect normal lineages for blood cancer therapy
Breanna DiAndreth, Pavlo A. Nesterenko, Aaron Winters, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Page 1 - Next Page

Scroll to top